Skip to main content

Citius Pharmaceuticals, Inc. (CTXR) Stock Forecast

Data as of May 9, 2026

Healthcare · Current price $0.64 (-2.90%)

Consensus Target
Upside
Analysts
2
Rating
Buy(2.00)

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold0
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

No analyst price targets available.

CTXR vs Sector & Market

MetricCTXRHealthcare AvgLarge Cap Avg
Analyst Rating2.002.242.41
Analyst Count2819
Target Upside+1708.8%+16.4%
P/E Ratio-0.393.3027.60

Revenue Estimates

PeriodLowAvgHigh#
2026-09-30$74M$78M$82M1
2027-09-30$131M$144M$157M1
2028-09-30$175M$184M$193M1
2029-09-30$198M$209M$219M1
2030-09-30$211M$221M$232M1

EPS Estimates

PeriodLowAvgHigh#
2026-09-30$1.56$1.66$1.761
2027-09-30$2.61$2.79$2.971
2028-09-30$2.32$2.48$2.641
2029-09-30$2.65$2.83$3.011
2030-09-30$2.77$2.96$3.151

Frequently Asked Questions

What is the analyst consensus for CTXR?

The consensus among 2 analysts covering Citius Pharmaceuticals, Inc. (CTXR) is Buy with an average price target of N/A.

How many analysts cover CTXR?

2 analysts have issued ratings for Citius Pharmaceuticals, Inc. in the past 12 months.

Is CTXR a buy or sell right now?

Based on 2 analyst ratings, CTXR has a consensus rating of Buy (2.00/5) with a N/A upside to the consensus target of N/A.

What are the earnings estimates for CTXR?

Analysts estimate CTXR will report EPS of $1.66 for the period ending 2026-09-30, with revenue estimated at $78M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.